Literature DB >> 12955574

Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy.

Yasufumi Sato1.   

Abstract

Angiogenesis is regulated by the balance of pro-angiogenic factors and angiogenesis inhibitors, and the imbalance of these regulators is the cause of pathological angiogenesis, including tumor angiogenesis. Angiogenesis is required for tumor growth and metastasis, and thus constitutes an important target for the control of tumor progression. While the benefit of anti-angiogenic therapy is potentially profound, limitations have also been recognized by the results obtained thus far by clinical trials. Precise understanding of the process of angiogenesis should lead us to new regimens for more efficient anti-angiogenic therapy. This review focuses on our current understanding of the molecular mechanism of tumor angiogenic and the status of the anti-angiogenesis approach for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955574     DOI: 10.1007/s10147-003-0342-8

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  21 in total

1.  Hypoxia inducible factor-1 alpha and multiple myeloma.

Authors:  Archana Bhaskar; Bhupendra Nath Tiwary
Journal:  Int J Adv Res (Indore)       Date:  2016-01-01

2.  Migration and vascular lumen formation of endothelial cells in cancer cell spheroids of various sizes.

Authors:  Bishnubrata Patra; Yu-Sheng Peng; Chien-Chung Peng; Wei-Hao Liao; Yu-An Chen; Keng-Hui Lin; Yi-Chung Tung; Chau-Hwang Lee
Journal:  Biomicrofluidics       Date:  2014-09-09       Impact factor: 2.800

3.  From bench to bedside: the growing use of translational research in cancer medicine.

Authors:  Erin M Goldblatt; Wen-Hwa Lee
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

4.  Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab.

Authors:  Philip Weisshardt; Tanja Trarbach; Jan Dürig; Andreas Paul; Henning Reis; Derya Tilki; Inna Miroschnik; Süleyman Ergün; Diana Klein
Journal:  Histochem Cell Biol       Date:  2011-12-23       Impact factor: 4.304

Review 5.  The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research.

Authors:  Beatriz Dal Pont Duarte; Diego Bonatto
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-20       Impact factor: 4.553

6.  Targeting NRASQ61K mutant delays tumor growth and angiogenesis in non-small cell lung cancer.

Authors:  Zhaowei Song; Fenghai Liu; Jie Zhang
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

7.  Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells.

Authors:  Fatemeh Afkhami; Yves Durocher; Satya Prakash
Journal:  J Biomed Biotechnol       Date:  2010-10-14

8.  Stem-like ovarian cancer cells can serve as tumor vascular progenitors.

Authors:  Ayesha B Alvero; Han-Hsuan Fu; Jennie Holmberg; Irene Visintin; Liora Mor; Carlos Cano Marquina; Jessica Oidtman; Dan-Arin Silasi; Gil Mor
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

9.  The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents.

Authors:  Daekyu Sun; Wei-Jun Liu; Kexiao Guo; Jadrian J Rusche; Scot Ebbinghaus; Vijay Gokhale; Laurence H Hurley
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

10.  Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells.

Authors:  Maria T Mochin; Karen F Underwood; Brandon Cooper; John C McLenithan; Adam D Pierce; Cesar Nalvarte; Jack Arbiser; Anna I Karlsson; Alexander R Moise; Jackob Moskovitz; Antonino Passaniti
Journal:  Microvasc Res       Date:  2014-10-02       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.